In conclusion, although adjuvant IFN failed to show a generalized effect on prevention of HCC recurrence after curative resection, it effectively reduced late recurrence due to new tumor foci in pure-HCV patient adherent to therapy (i.e.: receiving at least 80% of IFN dose for at least 80% of time).